Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Osteoarthritis (OA) is a disease characterized by degeneration of cartilage or wear and tear. OA is a cause of disability and health issues. It is a disease that affects more than 500 million adults annually worldwide, of which India accounts for about 22 to 39% of OA patients. The most common type of osteoarthritis is knee OA. Pathogenesis of OA requires evolution in basic science and clinical research to enhance our understanding of the pathogenesis and as well as different treatment options. It is mainly classified as primary and secondary OA. The treatment for OA can only reduce the symptoms and cannot cure the disease itself, including pharmacological treatment, like non-steroidal anti-inflammatory drugs (NSAIDs), acting on COX1 (cyclooxygenase 1) and COX2 (cyclooxygenase 2) enzymes. Non-pharmacological treatments for OA include exercise like walking, and aerobic exercise, diet, weight loss, hot and cold therapy, as well as electrotherapy, which improves muscle strength and decreases joint pain. Surgical treatment is the last treatment option for OA patients, which includes arthroscopy and joint replacement therapy. Thus, necessary precautions should be taken for joints to be healthy and disease-free.

Download full-text PDF

Source
http://dx.doi.org/10.2174/0125899775267865231115051056DOI Listing

Publication Analysis

Top Keywords

treatment
5
review osteoarthritis
4
osteoarthritis eradication
4
eradication approaches
4
approaches update
4
update osteoarthritis
4
osteoarthritis disease
4
disease characterized
4
characterized degeneration
4
degeneration cartilage
4

Similar Publications

Aims: To assess self-reported practices and knowledge of nurses and prescribers (i.e., physicians and nurse practitioners) on intravenous fluid therapy, and to evaluate how this is documented through a clinical documentation review.

View Article and Find Full Text PDF

Objective: To evaluate the clinical characteristics, social deprivation, insurance coverage, and medication use across regional subsets of patients with psoriatic arthritis (PsA) in the US.

Methods: A cross-sectional study of PsA patients in the Rheumatology Informatics System for Effectiveness (RISE) registry between January 2020 and March2023 was conducted. Distribution of high disease activity (HDA - RAPID3>12), high comorbidity (RxRisk ≥90 percentile), high Area Deprivation Index (ADI ≥80), insurance coverage, prednisone ≥10mg daily, and all DMARD therapies across geographic regions were evaluated.

View Article and Find Full Text PDF

Wild-type p53 overexpression in -mutated acute myeloid leukemia: potential implications for disease biology and therapy response.

Haematologica

September 2025

Division of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, NY; Multiparametric In Situ Imaging (MISI) Laboratory, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York.

Not available.

View Article and Find Full Text PDF

Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by systemic inflammation and lymphadenopathy. Two major clinical subtypes, idiopathic plasmacytic lymphadenopathy (iMCD-IPL) and iMCD with thrombocytopenia, anasarca, fever, renal dysfunction/reticulin fibrosis, and organomegaly (iMCD-TAFRO), exhibit distinct pathophysiologic mechanisms. While interleukin-6 (IL-6) is known to be elevated in iMCD, the differences in IL-6 production sources between subtypes remain unclear.

View Article and Find Full Text PDF